Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Drug Class Review: Triptans: Final Report Update 4 [Internet].

Helfand M, Peterson K.

Portland (OR): Oregon Health & Science University; 2009 Jun.

2.

Comparative aspects of triptans in treating migraine.

Adelman JU, Lewit EJ.

Clin Cornerstone. 2001;4(3):53-64. Review.

PMID:
12739316
3.

Rational migraine management: optimising treatment with the triptans.

Millson DS.

Funct Neurol. 2000;15 Suppl 3:182-91. Review.

PMID:
11200789
4.

[Clinical use of triptans in the management of migraine].

Lantéri-Minet M.

CNS Drugs. 2006;20 Spec no.1:12-23. Review. French.

PMID:
16841523
5.

Triptans in pregnancy.

Soldin OP, Dahlin J, O'Mara DM.

Ther Drug Monit. 2008 Feb;30(1):5-9. doi: 10.1097/FTD.0b013e318162c89b. Review.

6.

Drug Class Review on Triptans: Final Report Update 3 [Internet].

Helfand M, Peterson K.

Portland (OR): Oregon Health & Science University; 2005 Nov.

7.

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

Millson DS, Tepper SJ, Rapoport AM.

Expert Opin Pharmacother. 2000 Mar;1(3):391-404. Review.

PMID:
11249525
8.

Sumatriptan: pharmacological basis and clinical results.

Dahlöf CG.

Curr Med Res Opin. 2001;17 Suppl 1:s35-45. Review.

PMID:
12463276
9.

The new triptans.

Gawel MJ.

Can J Clin Pharmacol. 1999 Autumn;6 Suppl A:20A-4A. Review.

PMID:
10494008
10.

Formulation Approaches of Triptans for Management of Migraine.

Kassem AA.

Curr Drug Deliv. 2016;13(6):882-98. Review.

PMID:
27109335
11.

Current and emerging second-generation triptans in acute migraine therapy: a comparative review.

Deleu D, Hanssens Y.

J Clin Pharmacol. 2000 Jul;40(7):687-700. Review.

PMID:
10883409
12.

Safety profile of the triptans.

Tepper SJ, Millson D.

Expert Opin Drug Saf. 2003 Mar;2(2):123-32. Review.

PMID:
12904112
13.

Menstrual Migraine and Treatment Options: Review.

Maasumi K, Tepper SJ, Kriegler JS.

Headache. 2017 Feb;57(2):194-208. doi: 10.1111/head.12978. Epub 2016 Dec 2. Review.

PMID:
27910087
14.

Drugs for the acute treatment of migraine in children and adolescents.

Richer L, Billinghurst L, Linsdell MA, Russell K, Vandermeer B, Crumley ET, Durec T, Klassen TP, Hartling L.

Cochrane Database Syst Rev. 2016 Apr 19;4:CD005220. doi: 10.1002/14651858.CD005220.pub2. Review.

PMID:
27091010
15.

Individual triptan selection in migraine attack therapy.

Belvís R, Pagonabarraga J, Kulisevsky J.

Recent Pat CNS Drug Discov. 2009 Jan;4(1):70-81. Review.

PMID:
19149716
16.

Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.

Tfelt-Hansen P.

J Headache Pain. 2011 Jun;12(3):275-80. doi: 10.1007/s10194-011-0309-5. Epub 2011 Feb 25. Review.

17.

Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability.

Pascual J, Mateos V, Roig C, Sanchez-Del-Rio M, Jiménez D.

Headache. 2007 Sep;47(8):1152-68. Review.

PMID:
17883520
18.

Pharmacological synergy: the next frontier on therapeutic advancement for migraine.

Blumenfeld A, Gennings C, Cady R.

Headache. 2012 Apr;52(4):636-47. doi: 10.1111/j.1526-4610.2011.02058.x. Epub 2012 Jan 6. Review.

PMID:
22221151
19.

Clinical applications of new therapeutic deliveries in migraine.

Dahlöf C.

Neurology. 2003 Oct 28;61(8 Suppl 4):S31-4. Review.

PMID:
14581656
20.

Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms.

Dodick DW, Martin V.

Cephalalgia. 2004 Jun;24(6):417-24. Review.

PMID:
15154851

Supplemental Content

Support Center